Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition
Where Today's News Shapes Tomorrow
